{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T21:38:41Z","timestamp":1788385121826,"version":"build-2803163510"},"reference-count":75,"publisher":"MJS Publishing, Medical Journals Sweden AB","license":[{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["AO"],"abstract":"<jats:p>Background and purpose: Tobacco smoking was prognostic in B-cell lymphomas in the pre-rituximab era, but the association with modern treatment, stage, subtypes, and survival outcomes remains unclear.\nPatient\/material and methods: All patients with diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) from Turku and Tampere University Hospitals 2009\u20132019 were identified. Population-based data from electronic medical records included demographics, tumour histology, Ann Arbor staging, and treatments. Smoking status was extracted with a deep learning-based natural language processing algorithm. Kaplan\u2013Meier overall survival (OS) estimates and adjusted hazard ratios (HRs) were calculated.\nResults: With a median follow-up of 96 months, 1,258 patients with DLBCL and 529 with FL were included. In DLBCL, the 5-year OS rate was 61%, 53%, and 45% among never, former, and persistent smokers, respectively. Persistent smoking remained an independent prognostic factor for shorter OS, HR 1.27 (95% confidence interval 1.10\u20131.60) after adjustment for comorbidities and completed treatment. The prognosis of FL was indolent with no difference in OS regardless of smoking status, with 5-year OS rates of 79%, 75%, and 74% among never, former, and persistent smokers, respectively. Smokers were younger at diagnosis, while other baseline demographics were similar. No differences in the systemic therapy use were observed between the different smoking categories in both FL and DLBCL.\nInterpretation: Overall and lymphoma-specific mortality is increased in persistent smokers with DLBCL compared with never smokers. Smoking prevention and cessation support remains of utmost importance.<\/jats:p>","DOI":"10.2340\/1651-226x.2025.44776","type":"journal-article","created":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T05:20:21Z","timestamp":1766035221000},"page":"1680-1687","source":"Crossref","is-referenced-by-count":1,"title":["Continuous tobacco smoking increases mortality in diffuse large B-cell lymphoma but not follicular lymphoma, a Finnish population-based study"],"prefix":"10.2340","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-1675-1436","authenticated-orcid":false,"given":"Taina","family":"Reunamo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1925-0192","authenticated-orcid":false,"given":"Erika","family":"Alanne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6706-4053","authenticated-orcid":false,"given":"Toni","family":"Mikkola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1556-3351","authenticated-orcid":false,"given":"Antti","family":"Karlsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5902-6182","authenticated-orcid":false,"given":"Antti","family":"Ellonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7062-8629","authenticated-orcid":false,"given":"Tarja","family":"Laitinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1469-5654","authenticated-orcid":false,"given":"Maarit","family":"B\u00e4rlund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7124-3515","authenticated-orcid":false,"given":"Pia","family":"\u00d6sterlund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5878-4333","authenticated-orcid":false,"given":"Heikki","family":"Minn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8265-511X","authenticated-orcid":false,"given":"Sirpa","family":"Lepp\u00e4","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6826-9354","authenticated-orcid":false,"given":"Sirkku","family":"Jyrkki\u00f6","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6134-1170","authenticated-orcid":false,"given":"Eetu","family":"Heerv\u00e4","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1183","published-online":{"date-parts":[[2025,12,17]]},"reference":[{"key":"136308","doi-asserted-by":"crossref","unstructured":"Thandra KC, Barsouk A, Saginala K, Padala SA, Barsouk A, Rawla P. Epidemiology of non-Hodgkin\u2019s lymphoma. Med Sci. 2021;9(1):5.","DOI":"10.3390\/medsci9010005"},{"key":"136309","doi-asserted-by":"crossref","unstructured":"doi: 10.3390\/medsci9010005.","DOI":"10.3390\/medsci9010005"},{"key":"136310","doi-asserted-by":"crossref","unstructured":"Lepp\u00e4 S, Meriranta L, Arffman M, J\u00f8rgensen J, Karjalainen-Lindsberg ML, Beiske K, et al. Biomarker-adapted treatment in high-risk large B-cell lymphoma. Hemasphere. 2025 May 12;9(5):e70139.","DOI":"10.1002\/hem3.70139"},{"key":"136311","doi-asserted-by":"crossref","unstructured":"doi: 10.1002\/hem3.70139.","DOI":"10.1002\/hem3.70139"},{"key":"136312","doi-asserted-by":"crossref","unstructured":"Martelli M, Ferreri AJM, Agostinelli C, Di Rocco A, Pfreundschuh M, Pileri SA. Diffuse large B-cell lymphoma. Crit Rev Oncol Hematol. 2013;87(2):146\u201371.","DOI":"10.1016\/j.critrevonc.2012.12.009"},{"key":"136313","doi-asserted-by":"crossref","unstructured":"doi: 10.1016\/j.critrevonc.2012.12.009.","DOI":"10.1016\/j.critrevonc.2012.12.009"},{"key":"136314","doi-asserted-by":"crossref","unstructured":"Hodgson DC, Mikhaeel NG. Consolidative radiation in DLBCL: evidence-based recommendations. Curr Oncol Rep. 2015;17(11):49.","DOI":"10.1007\/s11912-015-0472-y"},{"key":"136315","doi-asserted-by":"crossref","unstructured":"doi: 10.1007\/s11912-015-0472-y","DOI":"10.1007\/s11912-015-0472-y"},{"key":"136316","doi-asserted-by":"crossref","unstructured":"Cunningham D, Hawkes EA, Jack A, Qian W, Smith P, Mouncey P, et al. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. Lancet 2013;381:1817\u201326.","DOI":"10.1016\/S0140-6736(13)60313-X"},{"key":"136317","doi-asserted-by":"crossref","unstructured":"doi: 10.1016\/S0140-6736(13)60313-X","DOI":"10.1016\/S0140-6736(13)60313-X"},{"key":"136318","doi-asserted-by":"crossref","unstructured":"Pfreundschuh M, Tr\u00fcmper L, Osterborg A, Pettengell R, Trneny M, Imrie K, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006 May;7(5):379\u201391.","DOI":"10.1016\/S1470-2045(06)70664-7"},{"key":"136319","doi-asserted-by":"crossref","unstructured":"doi: 10.1016\/S1470-2045(06)70664-7","DOI":"10.1016\/S1470-2045(06)70664-7"},{"key":"136320","doi-asserted-by":"crossref","unstructured":"Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol. 2008;9(2):105\u201316.","DOI":"10.1016\/S1470-2045(08)70002-0"},{"key":"136321","doi-asserted-by":"crossref","unstructured":"doi: 10.1016\/S1470-2045(08)70002-0","DOI":"10.1016\/S1470-2045(08)70002-0"},{"key":"136322","doi-asserted-by":"crossref","unstructured":"Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G, Plantier I, Castaigne S, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte. Blood. 2010;116(12):2040\u20135.","DOI":"10.1182\/blood-2010-03-276246"},{"key":"136323","doi-asserted-by":"crossref","unstructured":"doi: 10.1182\/blood-2010-03-276246","DOI":"10.1182\/blood-2010-03-276246"},{"key":"136324","doi-asserted-by":"crossref","unstructured":"Harrysson S, Eloranta S, Ekberg S, Enblad G, Jerkeman M, Wahlin BE, et al. Incidence of relapsed\/refractory diffuse large B-cell lymphoma (DLBCL) including CNS relapse in a population-based cohort of 4243 patients in Sweden. Blood Cancer J. 2021;11(1):9.","DOI":"10.1038\/s41408-020-00403-1"},{"key":"136325","doi-asserted-by":"crossref","unstructured":"doi: 10.1038\/s41408-020-00403-1","DOI":"10.1038\/s41408-020-00403-1"},{"key":"136326","doi-asserted-by":"crossref","unstructured":"Geerdes EE, Durmaz M, Lugtenburg PJ, Chamuleau MED, Visser O, Issa DE, et al. No sex differential in relative survival among older patients with DLBCL treated with R-CHOP21: a population-based study. Blood Adv. 2023;7(17):4869\u201373.","DOI":"10.1182\/bloodadvances.2023010480"},{"key":"136327","doi-asserted-by":"crossref","unstructured":"doi: 10.1182\/bloodadvances.2023010480","DOI":"10.1182\/bloodadvances.2023010480"},{"key":"136328","doi-asserted-by":"crossref","unstructured":"Peyrade F, Jardin F, Thieblemont C, Thyss A, Emile JF, Castaigne S, et al. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2011;12(5):460\u20138.","DOI":"10.1016\/S1470-2045(11)70069-9"},{"key":"136329","doi-asserted-by":"crossref","unstructured":"doi: 10.1016\/S1470-2045(11)70069-9","DOI":"10.1016\/S1470-2045(11)70069-9"},{"key":"136330","doi-asserted-by":"crossref","unstructured":"Younes A, Sehn LH, Johnson P, Zinzani PL, Hong X, Zhu J, et al. Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non\u2013germinal center B-cell diffuse large B-cell lymphoma. J Clin Oncol. 2019;37(15):1285\u201395.","DOI":"10.1200\/JCO.18.02403"},{"key":"136331","doi-asserted-by":"crossref","unstructured":"doi: 10.1200\/JCO.18.02403","DOI":"10.1200\/JCO.18.02403"},{"key":"136332","doi-asserted-by":"crossref","unstructured":"Nowakowski GS, Chiappella A, Gascoyne RD, Scott DW, Zhang Q, Jurczak W, et al. ROBUST: a phase III study of lenalidomide plus R-CHOP versus placebo plus R-CHOP in previously untreated patients with ABC-type diffuse large B-cell lymphoma. J Clin Oncol. 2021;20;39(12):1317\u201328.","DOI":"10.1200\/JCO.20.01366"},{"key":"136333","doi-asserted-by":"crossref","unstructured":"doi: 10.1200\/JCO.20.01366","DOI":"10.1200\/JCO.20.01366"},{"key":"136334","doi-asserted-by":"crossref","unstructured":"Tilly H, Morschhauser F, Sehn LH, Friedberg JW, Trn\u011bn\u00fd M, Sharman JP, et al. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. N Engl J Med. 2022;386(4):351\u201363.","DOI":"10.1056\/NEJMoa2115304"},{"key":"136335","doi-asserted-by":"crossref","unstructured":"doi: 10.1056\/NEJMoa2115304","DOI":"10.1056\/NEJMoa2115304"},{"key":"136336","doi-asserted-by":"crossref","unstructured":"Batlevi CL, Sha F, Alperovich A, Ni A, Smith K, Ying Z, et al. Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups. Blood Cancer J. 2020 Jul 17;10(7):74.","DOI":"10.1038\/s41408-020-00340-z"},{"key":"136337","doi-asserted-by":"crossref","unstructured":"doi: 10.1038\/s41408-020-00340-z.","DOI":"10.1038\/s41408-020-00340-z"},{"key":"136338","doi-asserted-by":"crossref","unstructured":"Jacobsen E. Follicular lymphoma: 2023 update on diagnosis and management. Am J Hematol. 2022;97(12):1638\u201351.","DOI":"10.1002\/ajh.26737"},{"key":"136339","doi-asserted-by":"crossref","unstructured":"doi: 10.1002\/ajh.26737","DOI":"10.1002\/ajh.26737"},{"key":"136340","doi-asserted-by":"crossref","unstructured":"Battaglioli T, Gorini G, Costantini AS, Crosignani P, Miligi L, Nanni O, et al. Cigarette smoking and alcohol consumption as determinants of survival in non-Hodgkin\u2019s lymphoma: a population-based study. Ann Oncol. 2006;17(8):1283\u20139.","DOI":"10.1093\/annonc\/mdl096"},{"key":"136341","doi-asserted-by":"crossref","unstructured":"doi: 10.1093\/annonc\/mdl096","DOI":"10.1093\/annonc\/mdl096"},{"key":"136342","doi-asserted-by":"crossref","unstructured":"Geyer SM, Morton LM, Habermann TM, Allmer C, Davis S, Cozen W, et al. Smoking, alcohol use, obesity, and overall survival from non\u2010Hodgkin lymphoma: a population\u2010based study. Cancer. 2010;116(12):2993\u20133000.","DOI":"10.1002\/cncr.25114"},{"key":"136343","doi-asserted-by":"crossref","unstructured":"doi: 10.1002\/cncr.25114","DOI":"10.1002\/cncr.25114"},{"key":"136344","doi-asserted-by":"crossref","unstructured":"Talamini R, Polesel J, Spina M, Chimienti E, Serraino D, Zucchetto A, et al. The impact of tobacco smoking and alcohol drinking on survival of patients with non\u2010Hodgkin lymphoma. Int J Cancer. 2008;1;122(7):1624\u20139.","DOI":"10.1002\/ijc.23205"},{"key":"136345","doi-asserted-by":"crossref","unstructured":"doi: 10.1002\/ijc.23205","DOI":"10.1002\/ijc.23205"},{"key":"136346","doi-asserted-by":"crossref","unstructured":"Ollberding NJ, Evens AM, Aschebrook-Kilfoy B, Caces DB, Weisenburger DD, Smith SM, et al. Pre\u2010diagnosis cigarette smoking and overall survival in non\u2010 Hodgkin lymphoma. Br J Haematol. 2013;163(3):352\u20136.","DOI":"10.1111\/bjh.12512"},{"key":"136347","doi-asserted-by":"crossref","unstructured":"doi: 10.1111\/bjh.12512","DOI":"10.1111\/bjh.12512"},{"key":"136348","unstructured":"Wang Y, Tao H, Paxton RJ, Wang J, Mubarik S, Jia Y, et al. Post-diagnosis smoking and risk of cardiovascular, cancer, and all-cause mortality in survivors of 10 adult cancers: a prospective cohort study. Am J Cancer Res. 2019;9(11):2493\u2013514."},{"key":"136349","doi-asserted-by":"crossref","unstructured":"Odutola MK, van Leeuwen MT, Turner J, Bruinsma F, Seymour JF, Prince HM, et al. Associations between smoking and alcohol and follicular lymphoma incidence and survival: a family-based case-control study in Australia. Cancers. 2022;14(11):2710.","DOI":"10.3390\/cancers14112710"},{"key":"136350","doi-asserted-by":"crossref","unstructured":"doi: 10.3390\/cancers14112710","DOI":"10.3390\/cancers14112710"},{"key":"136351","doi-asserted-by":"crossref","unstructured":"Ekstr\u00f6m-Smedby K. Epidemiology and etiology of non-Hodgkin lymphoma \u2013 a review. Acta Oncol. 2006;45(3):258\u201371.","DOI":"10.1080\/02841860500531682"},{"key":"136352","doi-asserted-by":"crossref","unstructured":"doi: 10.1080\/02841860500531682","DOI":"10.1080\/02841860500531682"},{"key":"136353","doi-asserted-by":"crossref","unstructured":"Morton LM, Hartge P, Holford TR, Holly EA, Chiu BC, Vineis P, et al. Cigarette smoking and risk of non-Hodgkin lymphoma: a pooled analysis from the International Lymphoma Epidemiology Consortium (interlymph). Cancer Epidemiol Biomarkers Prev. 2005;14(4):925\u201333.","DOI":"10.1158\/1055-9965.EPI-04-0693"},{"key":"136354","doi-asserted-by":"crossref","unstructured":"doi: 10.1158\/1055-9965.EPI-04-0693","DOI":"10.1158\/1055-9965.EPI-04-0693"},{"key":"136355","doi-asserted-by":"crossref","unstructured":"Sch\u00f6llkopf C, Smedby KE, Hjalgrim H, Rostgaard K, Gadeberg O, Roos G, et al. Cigarette smoking and risk of non-Hodgkin\u2019s lymphoma \u2013 a population-based case-control study. Cancer Epidemiol Biomarkers Prev. 2005;14(7):1791\u20136.","DOI":"10.1158\/1055-9965.EPI-05-0077"},{"key":"136356","doi-asserted-by":"crossref","unstructured":"doi: 10.1158\/1055-9965.EPI-05-0077","DOI":"10.1158\/1055-9965.EPI-05-0077"},{"key":"136357","doi-asserted-by":"crossref","unstructured":"Diver WR, Patel AV, Thun MJ, Teras LR, Gapstur SM. The association between cigarette smoking and non-Hodgkin lymphoid neoplasms in a large US cohort study. Cancer Causes Control. 2012;23(8):1231\u201340.","DOI":"10.1007\/s10552-012-0001-3"},{"key":"136358","doi-asserted-by":"crossref","unstructured":"doi: 10.1007\/s10552-012-0001-3","DOI":"10.1007\/s10552-012-0001-3"},{"key":"136359","doi-asserted-by":"crossref","unstructured":"Anttalainen A, Ukkola-Vuoti L, Vihervaara V, Silvola S, Kuittinen O. Population based registry study on large B-cell lymphoma mortality and morbidity in Finland. Acta Oncol. 2025 Feb 25;64:303\u201311.","DOI":"10.2340\/1651-226X.2025.42539"},{"key":"136360","doi-asserted-by":"crossref","unstructured":"doi: 10.2340\/1651-226X.2025.42539.","DOI":"10.2340\/1651-226X.2025.42539"},{"key":"136361","doi-asserted-by":"crossref","unstructured":"Dai X, Gil GF, Reitsma MB, Ahmad NS, Anderson JA, Bisignano C, et al. Health effects associated with smoking: a burden of proof study. Nat Med. 2022 Oct;28(10):2045\u201355.","DOI":"10.1038\/s41591-022-01978-x"},{"key":"136362","doi-asserted-by":"crossref","unstructured":"doi: 10.1038\/s41591-022-01978-x","DOI":"10.1038\/s41591-022-01978-x"},{"key":"136363","doi-asserted-by":"crossref","unstructured":"Groenset C, Bech MN, Jarden M, H\u00f8gdal N, Hutchings M, Suetta C, et al. The effectiveness of exercise-based interventions on muscle mass, muscle strength, functional performance, aerobic capacity, and health-related quality of life in adults with malignant lymphoma undergoing chemotherapy: a systematic review of randomized controlled trials. Acta Oncol. 2025 Jan 28;64:129\u201342.","DOI":"10.2340\/1651-226X.2025.42056"},{"key":"136364","doi-asserted-by":"crossref","unstructured":"doi: 10.2340\/1651-226X.2025.42056","DOI":"10.2340\/1651-226X.2025.42056"},{"key":"136365","doi-asserted-by":"crossref","unstructured":"Karlsson A, Ellonen A, Irjala H, V\u00e4liaho V, Mattila K, Nissi L, et al. Impact of deep learning-determined smoking status on mortality of cancer patients: never too late to quit. ESMO Open. 2021;6(3):100175.","DOI":"10.1016\/j.esmoop.2021.100175"},{"key":"136366","doi-asserted-by":"crossref","unstructured":"doi: 10.1016\/j.esmoop.2021.100175","DOI":"10.1016\/j.esmoop.2021.100175"},{"key":"136367","doi-asserted-by":"crossref","unstructured":"Hirvonen E, Karlsson A, Saaresranta T, Laitinen T. Documentation of the patient\u2019s smoking status in common chronic diseases \u2013 analysis of medical narrative reports using the ULMFiT based text classification. Eur Clin Respir J. 2021;23;8(1):2004664.","DOI":"10.1080\/20018525.2021.2004664"},{"key":"136368","doi-asserted-by":"crossref","unstructured":"doi: 10.1080\/20018525.2021.2004664","DOI":"10.1080\/20018525.2021.2004664"},{"key":"136369","doi-asserted-by":"crossref","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373\u201383.","DOI":"10.1016\/0021-9681(87)90171-8"},{"key":"136370","doi-asserted-by":"crossref","unstructured":"doi: 10.1016\/0021-9681(87)90171-8","DOI":"10.1016\/0021-9681(87)90171-8"},{"key":"136371","doi-asserted-by":"crossref","unstructured":"Scott DW, Mottok A, Ennishi D, Wright GW, Farinha P, Ben-Neriah S, et al. Prognostic significance of diffuse large B-cell lymphoma cell of origin determined by digital gene expression in formalin-fixed paraffin-embedded tissue biopsies. J Clin Oncol. 2015; 10;33(26):2848\u201356.","DOI":"10.1200\/JCO.2014.60.2383"},{"key":"136372","doi-asserted-by":"crossref","unstructured":"doi: 10.1200\/JCO.2014.60.2383","DOI":"10.1200\/JCO.2014.60.2383"},{"key":"136373","doi-asserted-by":"crossref","unstructured":"Roschewski M, Phelan JD, Wilson WH. Molecular classification and treatment of diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma. Cancer J. 2020;26(3):195\u2013205.","DOI":"10.1097\/PPO.0000000000000450"},{"key":"136374","doi-asserted-by":"crossref","unstructured":"doi: 10.1097\/PPO.0000000000000450","DOI":"10.1097\/PPO.0000000000000450"},{"key":"136375","doi-asserted-by":"crossref","unstructured":"Bell DA, Liu Y, Cortopassi GA. Occurrence of bcl-2 oncogene translocation with increased frequency in the peripheral blood of heavy smokers. J Natl Cancer Inst. 1995;87(3):223\u20134.","DOI":"10.1093\/jnci\/87.3.223"},{"key":"136376","doi-asserted-by":"crossref","unstructured":"doi: 10.1093\/jnci\/87.3.223","DOI":"10.1093\/jnci\/87.3.223"},{"key":"136377","doi-asserted-by":"crossref","unstructured":"Nogai H, D\u00f6rken B, Lenz G. Pathogenesis of non-Hodgkin\u2019s lymphoma. J Clin Oncol. 2011;29(14):1803\u201311.","DOI":"10.1200\/JCO.2010.33.3252"},{"key":"136378","doi-asserted-by":"crossref","unstructured":"doi: 10.1200\/JCO.2010.33.3252","DOI":"10.1200\/JCO.2010.33.3252"},{"key":"136379","doi-asserted-by":"crossref","unstructured":"Barrans S, Crouch S, Smith A, Turner K, Owen R, Patmore R, et al. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. J Clin Oncol. 2010;28(20):3360\u20135.","DOI":"10.1200\/JCO.2009.26.3947"},{"key":"136380","doi-asserted-by":"crossref","unstructured":"doi: 10.1200\/JCO.2009.26.3947.","DOI":"10.1200\/JCO.2009.26.3947"},{"key":"136381","doi-asserted-by":"crossref","unstructured":"Tsuyama N, Sakata S, Baba S, Mishima Y, Nishimura N, Ueda K, et al. BCL2 expression in DLBCL: reappraisal of immunohistochemistry with new criteria for therapeutic biomarker evaluation. Blood. 2017;130(4):489\u2013500.","DOI":"10.1182\/blood-2016-12-759621"},{"key":"136382","doi-asserted-by":"crossref","unstructured":"doi: 10.1182\/blood-2016-12-759621","DOI":"10.1182\/blood-2016-12-759621"}],"container-title":["Acta Oncologica"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/actaoncologica\/article\/download\/44776\/52336","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actaoncologica\/article\/download\/44776\/52336","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T05:20:33Z","timestamp":1766035233000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/actaoncologica\/article\/view\/44776"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,17]]},"references-count":75,"URL":"https:\/\/doi.org\/10.2340\/1651-226x.2025.44776","relation":{},"ISSN":["1651-226X"],"issn-type":[{"value":"1651-226X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,17]]}}}